AstraZeneca has struck a $1bn (£773m) deal to buy a Belgian biotech company that specialises in cancer immunotherapies, the latest in a string of acquisitions that also yielded positive results for a late-stage rare disease drug on Monday.
EsoBiotec, a small privately held firm, develops in-vivo CAR-T cell therapies that empower the immune system to attack cancers, and could offer many more patients access to cell therapy treatments, provided in minutes rather than weeks.
The deal marks the latest acquisition by AstraZeneca, which is Britain’s biggest listed company valued at £184bn, as the pharmaceutical group continues to expand its global operations. Its share price fell by 1.2% on Monday afternoon.
Read Full Article Here